LONDON, December 14 /PRNewswire/ --
- Second Appraisal Consultation Document Fails to Provide Choice for Patients and Ophthalmologists
Pfizer Limited today expresses concern that the latest NICE appraisal consultation document (ACD) regarding the use of treatments for wet Age-related Macular Degeneration (AMD), fails to provide any treatment choice for patients or physicians, by recommending only one anti-VEGF therapy for AMD.
NICE's second ACD again fails to recommend Macugen(R) (pegaptanib) for patients affected by wet AMD in England and Wales, in stark contrast to Scotland where the Scottish Medicines Consortium (SMC) approved its use.